Cargando…

Sero-prevalence of hepatitis B and C viral infections in Ghanaian HIV positive cohort: a consideration for their health care

BACKGROUND: Antiretroviral therapy (ART) has significantly decreased HIV/AIDS-related morbidity and mortality. However, globally, many people living with HIV die from non-AIDS related illnesses including liver diseases which occur partly due to co-infection with HBV and or HCV. The aim of this study...

Descripción completa

Detalles Bibliográficos
Autores principales: Pappoe, Faustina, Hagan, Charles Kofi Oheneba, Obiri-Yeboah, Dorcas, Nsiah, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6499983/
https://www.ncbi.nlm.nih.gov/pubmed/31053100
http://dx.doi.org/10.1186/s12879-019-4027-y
_version_ 1783415864486264832
author Pappoe, Faustina
Hagan, Charles Kofi Oheneba
Obiri-Yeboah, Dorcas
Nsiah, Paul
author_facet Pappoe, Faustina
Hagan, Charles Kofi Oheneba
Obiri-Yeboah, Dorcas
Nsiah, Paul
author_sort Pappoe, Faustina
collection PubMed
description BACKGROUND: Antiretroviral therapy (ART) has significantly decreased HIV/AIDS-related morbidity and mortality. However, globally, many people living with HIV die from non-AIDS related illnesses including liver diseases which occur partly due to co-infection with HBV and or HCV. The aim of this study was to determine the seroprevalence of HBV and HCV among HIV infected individuals receiving care from three different hospitals in the Central Region of Ghana. METHODS: This research was a case-case study. The population consisted of ART naive persons (newly confirmed HIV cases) and those who had been on ART for more than 3 months (old cases). Each individual’s sociodemographic characteristics and clinical data including their HBV and HCV status were collected. Those who knew their HBV and HCV status and those who did not know their status were tested for circulating HBsAg and anti-HCV using rapid diagnostic test cassettes. Descriptive analysis was done, and the data presented as median with interquartile range, frequency and percentage. Fisher’s exact test and Pearson Chi-square (χ(2)) test were used to determine associations between categorical variables. RESULTS: Overall, 394 HIV individuals aged, 3 to 76 years old with a median age of 41 (IQR:34–49) participated in this study. Circulating HBsAg and anti-HCV were detected in 6.1% (24/394) and 0.5% (2/393) participants respectively with an overall seroprevalence of 6.6% (26/394). None of the participants was positive for both HBV and HCV infections. 92.1% (363/394) had no information on their HBV status while all the 394 participants did not know their HCV status during data collection. No significant association of HBV infection rate was found in all the socio-demographic data of the participants. But HBV infection rates were significantly higher in those at WHO clinical stages 2 and 3 (P = 0.004). CONCLUSION: HBV and HCV were detected among the HIV-infected participants. Majority of the participants had no information on their HBV status and none of the participants had information on his or her HCV status. This study recommends the need for policy makers to provide free HBV and HCV screening for all HIV infected individuals for their effective management.
format Online
Article
Text
id pubmed-6499983
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-64999832019-05-09 Sero-prevalence of hepatitis B and C viral infections in Ghanaian HIV positive cohort: a consideration for their health care Pappoe, Faustina Hagan, Charles Kofi Oheneba Obiri-Yeboah, Dorcas Nsiah, Paul BMC Infect Dis Research Article BACKGROUND: Antiretroviral therapy (ART) has significantly decreased HIV/AIDS-related morbidity and mortality. However, globally, many people living with HIV die from non-AIDS related illnesses including liver diseases which occur partly due to co-infection with HBV and or HCV. The aim of this study was to determine the seroprevalence of HBV and HCV among HIV infected individuals receiving care from three different hospitals in the Central Region of Ghana. METHODS: This research was a case-case study. The population consisted of ART naive persons (newly confirmed HIV cases) and those who had been on ART for more than 3 months (old cases). Each individual’s sociodemographic characteristics and clinical data including their HBV and HCV status were collected. Those who knew their HBV and HCV status and those who did not know their status were tested for circulating HBsAg and anti-HCV using rapid diagnostic test cassettes. Descriptive analysis was done, and the data presented as median with interquartile range, frequency and percentage. Fisher’s exact test and Pearson Chi-square (χ(2)) test were used to determine associations between categorical variables. RESULTS: Overall, 394 HIV individuals aged, 3 to 76 years old with a median age of 41 (IQR:34–49) participated in this study. Circulating HBsAg and anti-HCV were detected in 6.1% (24/394) and 0.5% (2/393) participants respectively with an overall seroprevalence of 6.6% (26/394). None of the participants was positive for both HBV and HCV infections. 92.1% (363/394) had no information on their HBV status while all the 394 participants did not know their HCV status during data collection. No significant association of HBV infection rate was found in all the socio-demographic data of the participants. But HBV infection rates were significantly higher in those at WHO clinical stages 2 and 3 (P = 0.004). CONCLUSION: HBV and HCV were detected among the HIV-infected participants. Majority of the participants had no information on their HBV status and none of the participants had information on his or her HCV status. This study recommends the need for policy makers to provide free HBV and HCV screening for all HIV infected individuals for their effective management. BioMed Central 2019-05-03 /pmc/articles/PMC6499983/ /pubmed/31053100 http://dx.doi.org/10.1186/s12879-019-4027-y Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Pappoe, Faustina
Hagan, Charles Kofi Oheneba
Obiri-Yeboah, Dorcas
Nsiah, Paul
Sero-prevalence of hepatitis B and C viral infections in Ghanaian HIV positive cohort: a consideration for their health care
title Sero-prevalence of hepatitis B and C viral infections in Ghanaian HIV positive cohort: a consideration for their health care
title_full Sero-prevalence of hepatitis B and C viral infections in Ghanaian HIV positive cohort: a consideration for their health care
title_fullStr Sero-prevalence of hepatitis B and C viral infections in Ghanaian HIV positive cohort: a consideration for their health care
title_full_unstemmed Sero-prevalence of hepatitis B and C viral infections in Ghanaian HIV positive cohort: a consideration for their health care
title_short Sero-prevalence of hepatitis B and C viral infections in Ghanaian HIV positive cohort: a consideration for their health care
title_sort sero-prevalence of hepatitis b and c viral infections in ghanaian hiv positive cohort: a consideration for their health care
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6499983/
https://www.ncbi.nlm.nih.gov/pubmed/31053100
http://dx.doi.org/10.1186/s12879-019-4027-y
work_keys_str_mv AT pappoefaustina seroprevalenceofhepatitisbandcviralinfectionsinghanaianhivpositivecohortaconsiderationfortheirhealthcare
AT hagancharleskofioheneba seroprevalenceofhepatitisbandcviralinfectionsinghanaianhivpositivecohortaconsiderationfortheirhealthcare
AT obiriyeboahdorcas seroprevalenceofhepatitisbandcviralinfectionsinghanaianhivpositivecohortaconsiderationfortheirhealthcare
AT nsiahpaul seroprevalenceofhepatitisbandcviralinfectionsinghanaianhivpositivecohortaconsiderationfortheirhealthcare